Published in Scand J Urol Nephrol on January 01, 2003
Randomised prostate cancer screening trial: 20 year follow-up. BMJ (2011) 6.50
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract (2006) 0.95
Genetic variation in the upstream region of ERG and prostate cancer. Cancer Causes Control (2009) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Randomised prostate cancer screening trial: 20 year follow-up. BMJ (2011) 6.50
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer (2005) 3.51
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol (2012) 2.79
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer (2006) 2.69
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol (2012) 2.28
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol (2009) 2.22
How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol (2006) 2.21
Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate (2004) 2.19
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol (2008) 2.17
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol (2012) 1.96
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int (2010) 1.94
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol (2012) 1.88
Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol (2008) 1.83
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA (2006) 1.81
Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev (2009) 1.78
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol (2010) 1.75
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet (2010) 1.74
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol (2008) 1.74
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol (2009) 1.72
Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol (2004) 1.71
Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol (2013) 1.64
Causes of death in the Sami population of Sweden, 1961-2000. Int J Epidemiol (2005) 1.60
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A (2010) 1.59
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate (2005) 1.56
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst (2005) 1.55
Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch (2006) 1.48
Self-guided psychological treatment for depressive symptoms: a meta-analysis. PLoS One (2011) 1.47
Validity of a population-based cancer register in Sweden--an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol (2003) 1.47
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol (2014) 1.46
Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis (2008) 1.45
Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep (2007) 1.43
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
A prospective study of nosocomial urinary tract infection in hip fracture patients. J Clin Nurs (2011) 1.42
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
[Swedish medical research does not need more control]. Lakartidningen (2014) 1.39
Inguinal hernia after radical prostatectomy for prostate cancer: results from a randomized setting and a nonrandomized setting. Eur Urol (2010) 1.39
Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate (2009) 1.37
Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. Eur J Cancer (2007) 1.35
Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int (2004) 1.33
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer (2009) 1.32